New injection could calm stubborn hives
NCT ID NCT07181369
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This early-stage study tests a single dose of a new drug, GTX-B001, for safety. First, healthy volunteers receive the drug to check for side effects. Then, people with chronic inducible urticaria (hives triggered by cold or pressure) receive it to see if it helps. The goal is to find a safe dose and gather early signs of symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organization gmbh
RECRUITINGBerlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fraunhofer Institute For Translational Medicine And Pharmacology
NOT_YET_RECRUITINGBerlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.